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Viral double-stranded RNA (dsRNA) activates protein kinase R (PKR), which phosphorylates eIF2a and
inhibits translation. In response, viruses have evolved various strategies to evade the antiviral impact of
PKR. We investigated whether guinea pig cytomegalovirus (GPCMV), a useful model of congenital CMV
infection, encodes a gene that interferes with the PKR pathway. Using a proteomic screen, we identiﬁed
several GPCMV dsRNA-binding proteins, among which only gp145 rescued replication of a vaccinia
virus mutant that lacks E3L. gp145 also reversed the inhibitory effects of PKR on expression of a
cotransfected reporter gene. Mapping studies demonstrated that the gp145 dsRNA-binding domain has
homology to the PKR antagonists of other CMVs. However, dsRNA-binding by gp145 is not sufﬁcient for
it to block PKR. gp145 differs from the PKR antagonists of murine CMV in that it functions alone and
from those encoded by human CMV in functioning in cells from both primates and rodents.
& 2012 Elsevier Inc. All rights reserved.Introduction
Human cytomegalovirus (HCMV) is the most common viral
infection in newborns, infecting between 0.5% and 2% of infants in
utero (Demmler, 1996). Each year in the United States there are
over 5500 congenital HCMV infections that result in permanent
neurologic disability or death (Bate et al., 2010). HCMV is thought
to have coevolved with humans (McGeoch et al., 2006) and
replicates well only in human cells. This species-speciﬁcity pre-
cludes the study of HCMV in animal models and has led to the
development of several primate and rodent CMVs as models for
studying pathogenesis of and immunity to HCMV (Barry et al.,
2006; Powers and Fruh, 2008; Schleiss, 2006). Among these,ll rights reserved.
ogy, Fred Hutchinson Cancer
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arch Center, 1100 Fairview
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oom 3-214 MTRF, 2001 6thguinea pig cytomegalovirus (GPCMV) is a particularly valuable
model to study congenital infection since, like HCMV, GPCMV
crosses the placenta and infects the developing fetus in utero
(Schleiss, 2006). Application of the GPCMV model requires an
understanding of the similarities and differences between GPCMV
and HCMV genes and mechanisms, particularly those involved in
evasion of rapidly evolving host defense systems.
Double-stranded RNA (dsRNA), which accumulates during the
replication of HCMV and many other viruses (Marshall et al.,
2009; Weber et al., 2006), activates several cellular antiviral
pathways, including one mediated by protein kinase R (PKR).
Upon binding to dsRNA, PKR dimerizes and autophosphorylates to
form active PKR, which then phosphorylates the a-subunit of
eukaryotic initiation factor 2 (eIF2a). Phosphorylated eIF2a inhi-
bits the activity of the guanine nucleotide exchange factor eIF2B
and thereby limits formation of the eIF2a-tRNAiMet-GTP ternary
complex, inhibiting translation initiation and viral replication
(Garcia et al., 2006).
To counteract the effects of PKR, many viruses have evolved
factors that block the pathway at one or more steps (Langland
et al., 2006; Mohr et al., 2007). In the case of HCMV, two genes,
IRS1 and TRS1, encode proteins that bind both to dsRNA and to
PKR, preventing PKR activation in human cells (Child et al., 2004;
Fig. 1. dsRNA-binding proteins produced during GPCMV infection. GPL cells
infected with GPCMV were radiolabeled with 35S at 4 days post infection, lysed,
and the proteins bound to control or poly I:C conjugated agarose beads were
visualized by autoradiography following SDS-PAGE. Regions indicated on the right
(1–5) correspond to samples isolated from a second experiment that were
analyzed by mass spectrometry (see Table 1).
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members of the b-herpesvirus US22 gene family, which also
includes PKR antagonists of MCMV (m142 and m143) and RhCMV
(rhTRS1). The proteins encoded by these genes all bind to dsRNA
and interact with PKR with varying species-speciﬁcities (Budt
et al., 2009; Child et al., 2012,2006; Valchanova et al., 2006).
Deletion of both the PKR antagonists of HCMV or either one from
MCMV eliminates viral replication (Marshall et al., 2009;
Valchanova et al., 2006). Productive infection can be restored to
these viruses by providing an active PKR antagonist in cis or trans
(Marshall et al., 2009; Valchanova et al., 2006) or, in the case of
MCMV, by abolishing PKR activity in infected cells (Budt et al.,
2009).
To better understand the function and evolution of PKR
inhibition by CMVs, we sought to identify a PKR antagonist
encoded by GPCMV. We found that gp145, a member of the
US22 protein family, binds to dsRNA and inhibits the PKR path-
way. gp145 shares a noncanonical dsRNA-binding domain and an
ability to multimerize with TRS1 and m142/m143. Also, like TRS1,
dsRNA-binding and self-association by gp145 are insufﬁcient to
antagonize PKR. Our results reveal that while dsRNA-binding is a
conserved feature of the CMV PKR antagonists, mechanistic
differences between GPCMV gp145 and the PKR antagonists of
other rodent and primate CMVs may reﬂect adaptations to
evolutionary changes in the PKR genes of their host species.Results
Identiﬁcation of GPCMV dsRNA-binding proteins
To test whether GPCMV encodes a PKR antagonist, we initially
investigated whether GPCMV infection could rescue a vaccinia
virus mutant (VVDE3L) that lacks its PKR antagonist E3L and thus
replicates poorly in many cell types (Beattie et al., 1996). VVDE3L
replication can be rescued by coinfection with a second virus that
blocks PKR (Jacobs et al., 1998), as was observed previously by
coinfection with HCMV and VVDE3L (Child et al., 2002). However,
VVDE3L replication was much less restricted in guinea pig lung
ﬁbroblasts (GPL) and other GPCMV-permissive cell lines than it is
in other cell types such as human ﬁbroblasts or HeLa cells. Prior
infection with GPCMV did not further increase VVDE3L replica-
tion in GPL cells (data not shown). We also tested whether a
second vaccinia protein, K3L (Beattie et al., 1991), might be acting
as the primary PKR antagonist in GPL cells but found that VVDK3L
also displayed only a modest growth defect in GPL cells and prior
infection with GPCMV resulted in no substantial rescue of
VVDK3L (data not shown). Thus we were unable to utilize rescue
of VVDE3L in GPCMV-permissive cell lines to determine whether
GPCMV encodes a PKR antagonist.
The unusually weak phenotypes of VVDE3L and VVDK3L
viruses in GPCMV-permissive cell lines led us to explore alter-
native means to screen for a GPCMV PKR antagonist. Because the
PKR antagonists of many viruses are dsRNA-binding proteins
(Child et al., 2012,2006; Hakki and Geballe, 2005; Langland
et al., 2006; Mohr et al., 2007), we hypothesized that a GPCMV
PKR antagonist might also bind dsRNA. To identify GPCMV
dsRNA-binding proteins, we incubated lysates from mock or
GPCMV-infected GPL cells with poly I:C agarose beads (Fig. 1) as
described in Materials and Methods. Several bands unique to
GPCMV infection were detected, and these likely represented
either viral or virally-induced host dsRNA-binding proteins. To
identify these proteins, the prominent bands were excised,
digested with trypsin, and subjected to liquid chromatography–
tandem mass spectrometry (Table 1). Several cellular dsRNA-
binding proteins were detected in this experiment, includingmammalian Staufen and ILF3 (Buaas et al., 1999; Ramos et al.,
2000), supporting the speciﬁcity of the poly I:C pull-down assay.
The most intense bands (72 and 47 kDa) corresponded to the
GPCMV proteins gp145 and GP44. gp145 is a member of the US22
gene family and has been annotated as a possible homologue of
HCMV TRS1, while GP44 is homologous to UL44, a HCMV DNA
polymerase accessory protein that has been previously shown to
interact with TRS1 (Schleiss et al., 2008; Strang et al., 2010).
gp145 was detected in multiple samples that migrated above and
below the predicted molecular weight of the protein, suggesting
that multiple or modiﬁed forms of gp145 might be produced
during infection. Alternatively, the smaller fragments could be
degradation products generated during sample preparation. Other
abundant GPCMV proteins identiﬁed in this screen included gp3,
a US22 family protein with no obvious homologue in HCMV, and
GP122, the GPCMV homologue of the HCMV IE2 transcriptional
transactivator. A third US22 family protein identiﬁed in this
experiment, gp139 (Schleiss et al., 2008), was not detected when
this experiment was repeated.
We next sought to differentiate direct dsRNA-binding by
GPCMV proteins from indirect binding as part of a multi-protein
complex. In addition to testing gp3, gp44, and gp145, we also
tested the dsRNA-binding of three additional US22 family pro-
teins that have some sequence similarity to TRS1 (gp141, gp144,
and gp146) but that were not detected in the proteomic analysis.
The GPCMV proteins were expressed by in vitro translation and
analyzed by the dsRNA-binding assay. With the exception of
gp141, which failed to express either by in vitro translation or
transient transfection, all of the GPCMV proteins tested bound to
the poly I:C beads (Fig. 2 and data not shown). To test the
speciﬁcity of the observed dsRNA-binding, the in vitro translation
products were preincubated with either DNA or poly I:C prior to
incubation with poly I:C beads. As expected, E3L binding to the
poly I:C beads was competed by dsRNA but not by DNA, and
gp145 binding was also more strongly competed by preincuba-
tion with dsRNA. The opposite pattern was observed from gp3
and GP44, suggesting that these proteins preferentially bind to
DNA. These experiments demonstrated GPCMV encodes several
dsRNA-binding proteins, although only gp145 appears to prefer-
entially bind dsRNA over DNA.
gp145 rescues VVDE3L
Having identiﬁed GPCMV proteins capable of dsRNA-binding,
we next tested their ability to inhibit the PKR pathway by
Table 1
dsRNA-binding proteins in GPCMV infected cells.
Samplea Gene # Pep.b % Cov.c MW (kDa) Gene function
1 ILF3 22 21.9 95.3 Interleukin enhancer binding factor 3
gp3 13 14.5 87.7 Homology to THV T5b; US22 superfamily
gp145 10 12.0 68.9 Homology to HCMV IRS1/TRS1; US22 superfamily
GP69 7 7.0 116.3 UL69 homolog
GP122 6 13.7 35.4 UL122 homolog; HCMV IE2
2 ILF3 32 21.7 95.3 Interleukin enhancer binding factor 3
gp145 12 16.1 68.9 Homology to HCMV IRS1/TRS1; US22 superfamily
gp139 5 6.5 79.5 Homology to THV T5b; US22 superfamily
3 gp145 38 24.4 68.9 Homology to HCMV IRS1/TRS1; US22 superfamily
4 STAU1 22 23.7 62.2 Staufen, RNA binding protein, homolog 1
GP55 12 12.7 102.2 UL55 homolog; glycoprotein B
gp145 12 13.0 68.9 Homology to HCMV IRS1/TRS1; US22 superfamily
5 GP44 87 44.7 44.8 UL44 homolog, polymerase accessory protein
a See Fig. 1 for approximate regions of the gel represented in each sample.
b Number of peptides detected.
c Percent coverage.
Fig. 2. dsRNA-binding by in vitro translated GPCMV proteins. In vitro translated,
radiolabeled GPCMV and control (E3L and EGFP) proteins were bound to either
control or poly I:C conjugated agarose beads. To test the speciﬁcity of binding,
samples were preincubated with or without DNA or poly I:C competitor prior
to binding to poly I:C beads. 10% of the protein used in each binding reaction
was run as an input control. The samples were analyzed by SDS-PAGE and
autoradiography.
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replication (Jacobs et al., 1998). We transfected HeLa cells with
plasmids expressing the GPCMV proteins, infected the cells with
VVDE3L, and measured viral replication at 24 h post infection. Of
the GPCMV proteins tested, only gp145 rescued the replication of
VVDE3L (Fig. 3A). Similar results were also observed in African
green monkey cells (COS-7, data not shown). Unlike the MCMV
proteins m142 and m143, which function as a heteromeric
complex (Child et al., 2006), gp145 was both stably expressed
and sufﬁcient to rescue VVDE3L when expressed by itself. We
tested whether VVDE3L rescue by gp145 might be enhanced by
cotransfection of HeLa cells with both gp145 and either gp3,
GP44, gp144, gp146, or GFP, but observed no further increase in
VVDE3L replication by mixed transfection of GPCMV proteins
over the gp145 plus GFP control (data not shown).
Because GPCMV evolved in guinea pigs and its PKR antagonist
is likely to be most active against guinea pig PKR, we sought to
identify a guinea pig cell line with which we could assess rescue
of VVDE3L replication by transfection. We found that GPC-16 cells
(ATCC CCL-242), a transformed line of guinea pig epithelial cells,
are highly restrictive to VVDE3L replication. This cell line is notpermissive to GPCMV replication (Nozawa et al., 2008) and so we
could not use it to test whether GPCMV infection could rescue
VVDE3L replication. However, transient transfection of either
gp145 or E3L did rescue VVDE3L replication in GPC-16 cells
(Fig. 3B). TRS1 failed to rescue VVDE3L in GPC-16 cells, suggesting
that TRS1 may be inactive against guinea pig PKR. These results
demonstrated that gp145 can rescue VVDE3L replication in
human, African green monkey, and guinea pig cells and suggest
that gp145 activity against PKR is less species-speciﬁc than the
PKR antagonists of primate CMVs (Child et al., 2012). Additionally,
gp145 is more similar to the HCMV and RhCMV PKR antagonists
than to MCMV m142/m143 in that a single protein is sufﬁcient to
block the PKR pathway.
gp145 antagonizes PKR
Because E3L interferes with a number of cellular antiviral
pathways in addition to PKR (Perdiguero and Esteban, 2009), the
ability of a protein to rescue VVDE3L is only an indirect measure
of PKR antagonism. We sought additional evidence demonstrating
speciﬁc activity of gp145 against PKR, but the lack of available
guinea pig reactive reagents prevented us from assaying whether
gp145 can prevent phosphorylation of guinea pig PKR. Therefore,
we tested whether gp145 can block PKR by measuring its ability
to reverse the inhibitory effects of PKR on expression of cotrans-
fected reporter genes (Jacobs et al., 1998; Rothenburg et al.,
2009). We transfected plasmids expressing secreted alkaline
phosphatase (SEAP), human PKR or GFP, and either GFP, E3L,
TRS1, or gp145 into HeLa cells in which endogenous PKR has been
stably knocked down by an shRNA (Zhang and Samuel, 2007).
Expression of PKR with SEAP resulted in a 12-fold reduction in
protein expression relative to the GFP control (Fig. 4). E3L, TRS1,
and gp145 all rescued SEAP expression when coexpressed with
human PKR.
We observed that PKR expression was higher in cells that also
expressed a PKR antagonist. This suggests that active antagonists
enable increased expression of all transfected genes, including
PKR and the SEAP reporter, and has been observed by others
(Rothenburg et al., 2009). We suspect that the increase in PKR
expression ultimately overwhelms the antagonists and prevents
the full recovery of SEAP levels. To exclude the possibility that
increased SEAP expression is the result of an increased level of
transcription, we assessed the abundance of SEAP mRNA by
northern blot. While transfection of E3L and gp145 both increased
the abundance of SEAP mRNA, this effect did not result in a
signiﬁcant increase in SEAP production in the absence of PKR.
Fig. 3. gp145 rescues VVDE3L replication. (A) HeLa or (B) GPC-16 cells were transfected with the indicated plasmids and infected with VVDE3L 24 h later. Viral replication
was measured at 24 h post infection and the expression of the transfected proteins was measured by a-His immunoblot. E3L was not detectable in this blot because it is
not 6X-His-tagged.
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transcriptional transactivator (Romanowski and Shenk, 1997;
Stasiak and Mocarski, 1992), expression of TRS1 inhibited SEAP
mRNA and protein production in the absence of PKR. These results
support our conclusion from the previous VVDE3L rescue experi-
ments that gp145 antagonizes the PKR pathway.
dsRNA-binding activity maps to the gp145 US22 domain
Having demonstrated the anti-PKR activity of gp145, we next
sought to identify its functional domains. To delineate the dsRNA-
binding domain of gp145, we engineered a series of N- and C-
terminal gp145 truncations and analyzed their dsRNA-binding
properties (Fig. 5). gp145[187-632], [1-355], and all longer C-
terminal truncations bound to poly I:C beads at a level similar to
that of full length gp145 while the deletion of residues 1-355
(gp145[356-632]) eliminated dsRNA-binding activity. Both
gp145[1-186] and gp145[187-355] retained the ability to bind
dsRNA, although the level of binding was substantially reduced.
dsRNA-binding in TRS1 also maps to the N-terminus, and the
TRS1 minimal dsRNA-binding fragment (TRS1[74-246]) and
gp145[187-355] are among the most similar regions of the two
proteins, having 45% amino acid sequence similarity (Hakki and
Geballe, 2005). These data suggest that the gp145[187-355] and
TRS1[74-246] are a homologous dsRNA-binding domain and that
the common ancestor of these proteins predates the divergence of
human and guinea pig CMVs.
dsRNA-binding by gp145 is not sufﬁcient to rescue VVDE3L
In addition to the N-terminal dsRNA-binding domain, TRS1
requires most of its C-terminal end to rescue VVDE3L replicationand to bind to PKR (Hakki and Geballe, 2005; Hakki et al., 2006).
Outside of the shared US22 domain, gp145 and TRS1 are highly
divergent and gp145 lacks similarity to the C-terminal end of
TRS1 that is necessary for PKR interactions. We hypothesized that
gp145 functions primarily by binding and sequestering dsRNA;
such a mechanism is sufﬁcient for E3L to limit PKR activation in
cell culture (Shors et al., 1997). To evaluate the requirement of
dsRNA-binding and/or other regions of gp145 to antagonize PKR,
we tested a selection of gp145 truncations for their ability to
rescue VVDE3L replication following transfection of COS-7 cells.
Only full length gp145 and gp145[187-632] rescued the replica-
tion of VVDE3L (Fig. 6). Notably, gp145[1-355], gp145[1-512] and
gp145[1-566] all failed to rescue VVDE3L replication despite
having dsRNA-binding activity comparable to full length gp145
(Fig. 5). Similar results were observed in VVDE3L rescue experi-
ments in both HeLa and GPC-16 cells (data not shown). These
data led us to suspect that the C-terminus of gp145 provides some
function other than dsRNA-binding that is required for VVDE3L
rescue.
Because direct interaction with PKR appears to be a necessary
function of the PKR antagonists expressed by HCMV, MCMV, and
RhCMV (Child et al., 2012; Child and Geballe, 2009; Hakki et al.,
2006), we investigated whether gp145 could bind to PKR. In
cotransfection experiments, we detected only weak and incon-
sistent binding of gp145 to either human or guinea pig PKR (data
not shown). Thus, whether gp145 interacts with PKR remains
unclear, but we suspect there is a weak protein–protein interac-
tion between gp145 and PKR that might be facilitated by a dsRNA
tether.
MCMV m142 and m143 cooperatively bind dsRNA and both
are needed to block PKR (Child et al., 2006; Valchanova et al.,
2006), and we hypothesized that gp145 may need to multimerize
Fig. 4. gp145 inhibits the activity of PKR. HeLa PKR knockdown cells were
transfected with plasmids expressing SEAP, either knockdown-resistant human
PKR or GFP, and GFP, E3L, TRS1, or gp145. SEAP activity of the medium was
measured at 48 h post transfection. Expression of the transfected proteins was
measured by immunoblot. SEAP mRNA was detected by northern blot, and values
indicate the amount of transcript relative to the GFP control in each set of
transfections.
Fig. 5. The gp145 core dsRNA-binding domain maps amino acids 187-355. gp145
N- and C-terminal truncations were expressed by in vitro translation and pulled
down with either control or poly I:C beads. The numbers (left side) indicate the
amino acid range included in each gp145 plasmid (diagramed in Fig. 8). 5% of the
protein used in each binding reaction was run as an input control.
Fig. 6. The gp145 dsRNA-binding domain is not sufﬁcient to rescue VVDE3L. COS-
7 cells were transfected with gp145 truncations and infected with VVDE3L 24 h
later. Viral replication was measured at 24 h.p.i. by b-gal expression and the
expression of transfected proteins was monitored by a-His immunoblot.
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COS-7 cells with plasmids expressing biotin ligase and biotinyla-
tion signal-tagged gp145 along with full length or truncated 6X-
His-tagged gp145 expression plasmids. Following avidin pull-
down of the biotinylated gp145, we detected co-precipitated
6X-His-tagged proteins by immunoblot assay (Fig. 7). Three
gp145 constructs—full length, gp145[187-632] and gp145[1-
566]—co-precipitated with full length gp145, while the shorter
C-terminal truncations did not. Because gp145[1-566] interacted
with full length gp145 but did not rescue VVDE3L replication
(Fig. 6), gp145 self-interaction appears to be insufﬁcient for
PKR inhibition. Additionally, gp145 self-interaction cannot be
explained as exclusively mediated by a dsRNA bridge as several
truncations that bind dsRNA fail to self-interact, such as gp145[1-
355] and gp145[1-512]. Using this approach, we found that TRS1
also self-interacted. As with gp145, C-terminal truncations of
TRS1 that fail to rescue VVDE3L retain the ability to self-
associate and some truncations do not self-interact even though
they retain the dsRNA-binding activity (data not shown). In
summary, dsRNA-binding and self-interaction are common fea-
tures shared between gp145, TRS1, and the other known CMV
PKR antagonists. While these activities may be necessary for
gp145 function they appear to be insufﬁcient to rescue VVDE3L.
C-terminal residues of gp145 not required for dsRNA-binding may
either participate in another currently unidentiﬁed protein inter-
action or enhance dsRNA-binding to facilitate gp145 rescue of
VVDE3L replication.Discussion
PKR recognizes dsRNAs that accumulate during viral infection
and can inhibit viral replication by shutting down protein synth-
esis (Garcia et al., 2006; Weber et al., 2006). Viral dependence on
C.J. Bierle et al. / Virology 433 (2012) 157–166162the host translation machinery to replicate has led to the evolu-
tion of numerous viral strategies to antagonize PKR function.
In response, PKR has evolved rapidly during speciation, presum-
ably driven by selection to evade viral antagonists (Elde et al.,
2009; Rothenburg et al., 2009). The cytomegaloviruses are
believed to have cospeciated with their respective hosts over
the past 105 million years (McGeoch et al., 2006). As the diversity
of available host and viral genome sequences increases, CMVs
present a unique model to study the coevolution of host defenses
and viral countermeasures. Prior to this study, the PKR antago-
nists of two primate viruses (HCMV and RhCMV) and one rodent
virus (MCMV) had been characterized (Budt et al., 2009; ChildFig. 7. gp145 and TRS1 self-interact. COS-7 cells were transfected with plasmids
expressing biotin ligase, biotin signal-tagged gp145 or TRS1 as indicated at the
top, and with 6X-His tagged gp145 truncations, TRS1, or GFP. Biotinylated proteins
were pulled down by binding to avidin beads and detected with Avidex-AP (Av),
while associated proteins were detected by a-His immunoblot.
Fig. 8. Summary of gp145 domain mapping experiments. Shown are diagrams of the
regions of TRS1—the minimal dsRNA-binding domain and C-terminal residues neces
truncations used in Figs. 5–7 and summaries from the dsRNA-binding, VVDE3L rescueet al., 2012; Marshall et al., 2009; Valchanova et al., 2006). In this
study, we demonstrate that the GPCMV protein gp145 antago-
nizes the PKR pathway.
The ability to bind to dsRNA is a common feature of the PKR
antagonists encoded by many RNA viruses, poxviruses, and
herpesviruses (Chang et al., 1992; Child et al., 2012,2006; Hakki
and Geballe, 2005; Mohr and Gluzman, 1996; Poppers et al.,
2003). Thus, we suspected that a dsRNA-binding protein may
contribute to PKR inhibition in GPCMV, where no single protein
could be identiﬁed as an obvious homologue to either TRS1 or
m142/m143. We identiﬁed several viral dsRNA-binding proteins
present in GPCMV-infected cell lysates by mass spectrometry and
assessed their ability to rescue VVDE3L replication, a surrogate
measure of PKR antagonism (Jacobs et al., 1998). The GPCMV
protein gp145 was detected in this proteomic screen and subse-
quently found to bind dsRNA when translated in vitro, to rescue
VVDE3L replication, and to reverse the inhibitory effects of PKR
activation on the expression of a cotransfected reporter gene.
Like the PKR antagonists of HCMV, RhCMV, and MCMV, gp145
is a member of the US22 gene family, which is one of several gene
families unique to beta herpesviruses (Chee et al., 1990; Hansen
et al., 2003; Rawlinson et al., 1996; Schleiss et al., 2008; Weston
and Barrell, 1986). A recent study included the US22 family in the
SUKH gene superfamily, which predominantly includes bacterial
nuclease toxin-immunity systems (Zhang et al., 2011). Most US22
family proteins are comprised of 2 SUKH domains in tandem,
which are referred to here as SUKH1 and SUKH2 of TRS1 and
gp145 (Fig. 8). Little is known about either the function of most
US22 family proteins or the shared structural domain(s) of these
proteins (Menard et al., 2003). However, we found that dsRNA-
binding maps to the gp145 US22 domain, speciﬁcally to SUKH1,
as is the case for TRS1 (Fig. 8). As with MCMV, several GPCMV
US22 proteins bind dsRNA but only a subset of these proteins can
antagonize PKR (Child et al., 2006). It remains to be seen whether
binding to dsRNA or other nucleic acids plays a central role in the
presently uncharacterized functions of the other US22 proteins.
In addition to binding dsRNA, TRS1, rhTRS1, and m142/m143
all directly interact with PKR, in some cases in a species-speciﬁc
manner (Budt et al., 2009; Child et al., 2012; Child and Geballe,
2009; Hakki et al., 2006). gp145 lacks residues homologous to the
C-terminal end of TRS1 that are essential for interaction with
human PKR and for VVDE3L rescue. Our failure to identify robust
gp145-PKR interactions led us to speculate that the activity of
gp145 against PKR utilizes a mechanism that relied exclusively on
dsRNA-binding and sequestration. However, we observed that the
C-terminal half of gp145, which is dispensable for dsRNA-binding,approximate boundaries of the TRS1 and gp145 SUKH domains, along with two
sary for direct PKR-binding—that are essential for rescue of VVDE3L. The gp145
, and self-interaction experiments are also shown, unless not determined (ND).
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to m142 and m143, gp145 may need to multimerize to function.
While gp145 does self-interact, the region of gp145 that is
sufﬁcient for self-interaction is incapable of rescuing VVDE3L. It
remains unclear whether the function of the gp145 C-terminus in
intact cells is to potentiate binding to dsRNA or PKR, self-
interaction, or for some other interaction.
PKR has been found to be evolving under strong positive
selection in several mammalian lineages (Elde et al., 2009;
Rothenburg et al., 2009). Complex patterns of species-speciﬁcity
have been observed in the sensitivities of the vaccinia virus eIF2a
mimic K3L (Elde et al., 2009) and more recently in the anti-PKR
response of the TRS1 genes of HCMV and RhCMV (Child et al.,
2012). While human and rhesus CMV TRS1s are only active against
PKRs originating from close relatives of each virus’s natural host
(Child et al., 2012), gp145 appears to have activity against human,
African green monkey, and guinea pig PKRs. As previous studies
have found that MCMV m142 and m143 are active against human
and mouse PKR (Child et al., 2006; Valchanova et al., 2006), rodent
CMVs may have maintained a broader range of activity against
PKR genes than have the primate CMVs (Child et al., 2012).
Nonetheless, GPCMV and MCMV PKR differ in their requirement
for one versus two proteins to antagonize PKR (Child et al., 2006;
Valchanova et al., 2006). Such differences are not entirely surpris-
ing since mice and guinea pigs last shared a common ancestor
approximately 65 million years ago (Meredith et al., 2011) and the
GPCMV genome appears to be more similar to primate CMVs than
to MCMV (Schleiss et al., 2008).
Deletion of the PKR antagonists of either HCMV or MCMV
results in a replication incompetent virus. While this study does
not address whether gp145 is essential for GPCMV replication, a
previous study found that GPCMVDgp138-149 had an approxi-
mately three-log replication defect compared to wild type virus
while both Dgp123-143 and Dgp147-149 viruses replicated to
normal titers (Cui et al., 2009). These results are consistent with
the possibility that gp145 plays a critical role in efﬁcient GPCMV
replication. It is surprising that GPCMVDgp138-149 can replicate
at all in normal cells, since HCMVDIRS1/DTRS1 and MCMVDm142
or Dm143 cannot. However, the Dgp138-149 virus was propa-
gated in GPL cells, which we found also support the replication of
VVDE3L and VVDK3L. It is possible that GPL cells are less sensitive
to dsRNA accumulation or PKR activation than many other cell
types. Alternatively, as is the case for herpes simplex virus and
vaccinia virus (Davies et al., 1993; Mohr and Gluzman, 1996),
GPCMV may encode a second PKR antagonist that has yet to be
identiﬁed. Future analyses of a gp145 knockout virus will help
clarify these issues.
Viruses that lack a normal PKR response, such as VVDE3L, have
been explored as potential live-attenuated or disabled infectious
single cycle vaccines (Jentarra et al., 2008). The urgent need
for an effective vaccine to prevent congenital CMV infection and
the known replication defect of HCMVDIRS1/DTRS1 (Marshall
et al., 2009) make GPCMVDgp145 an attractive model for
vaccine development. GPCMV has an advantage over MCMV in
that the virus better models congenital infection and may require
only a single protein to antagonize PKR. That said, many
viral proteins are multifunctional and TRS1 is no exception.
Previous studies have demonstrated possible roles for TRS1 as a
coactivator with IE1 and IE2 transcriptional transactivators
(Romanowski and Shenk, 1997; Stasiak and Mocarski, 1992),
in virion assembly (Adamo et al., 2004), in viral DNA replication
(Pari et al., 1993; Strang et al., 2010), and in viral manipulation
of autophagy (Chaumorcel et al., 2012). Determining whether
gp145 shares any of these activities will be of great interest for
understanding the conserved roles of TRS1 and related US22
family proteins in viral replication and pathogenesis.Materials and methods
Cells and viruses
HeLa PKR knockdown cells (HeLa PKRKD) cells were provided
by Charles Samuel (University of California, Santa Barbara) (Zhang
and Samuel, 2007). GPL (ATCC CCL-158), HeLa, GPC-16 (ATCC
CCL-242), HeLa PKRKD, and COS-7 (ATCC CRL-1651) cells were
propagated on Dulbecco’s modiﬁed Eagle’s medium supplemen-
ted with 10% NuSerum (BD Biosciences) as previously described
(Child et al., 2004). VVDE3L, obtained from Bertram Jacobs
(Arizona State University), was propagated and titered in BHK
cells (Beattie et al., 1995; Child et al., 2004). GPCMV strain 22122
(ATTC VR682) was propagated and titered on GPL cells.
Plasmids
GPCMV genes were PCR ampliﬁed using the following oligonu-
cleotide pairs and cloned into pcDNA3.1/V5HisTOPO (Invitrogen):
pKTS777 (gp141, 50-ACCATGTGGCGACTGAACAG-30 and 50-TATCAGG-
TAGCTAGAAAAGT-30), pKTS778 (gp44, 50-ACCATGGAACGTAA-
GACGTC-30 and 50-GGCGGAACATTTCTGCTTCTT-30), pKTS780 (gp3,
50-ACCATGAAGCGATCGGAAGC-30 and 50-ATCGAGATCCAGTTC-
GAACG-30), pKTS784 (gp144, 50-ACCATGCCCAAGCTCGTCTC-30 and
50-GTTCTGATGTTTTCTCGGCG-30), pKTS786 (gp145, 50-ACCATGACC-
GAGGCGTTTC-30 and 50-GGAACACTCCTCGTCGCTGG-30), and
pEQ1396 (gp146, #960 50-ACCATGTCGCGTTCTGTATCTCG-30 and
#961 50-CGCGAGTCCCGTCGGG-30).
Two E3L-expressing plasmids were used in this study: pMTE3L
(Chang et al., 1992), generously provided by Bert Jacobs, was used
for transient transfections while pEQ1119 (Child et al., 2012) was
used for in vitro translation and dsRNA-binding assays. TRS1 was
expressed using pEQ1180 (formerly pEQ981) (Hakki and Geballe,
2005). An EGFP construct tagged with 6X-His only, pEQ1159, was
cloned from pEQ1100 (Child et al., 2006), which expresses GFP
tagged with both a biotinylation signal and 6X-His (Bio-His), by
digestion with EcoRV and SacII, blunted with Klenow, and ligated
to excise the biotinylation signal. Knockdown-resistant human
PKR (SR#329) was generously provided by Stefan Rothenburg
(Kansas State University) (Rothenburg et al., 2009). The SEAP
expression vector (pEQ886) has been previously described
(Janzen and Geballe, 2004). pEQ1338 was cloned by removing
the CMV and T7 promoters of the EGFP expressing pEQ1100 by
digestion with SspI and Asp718 and inserting a PvuII-Asp718
fragment from SR#329 containing the SV40 promoter and b-
Globin intron.
gp145 truncations were ampliﬁed from pKTS786 using either
the PCR Extender System (5 Prime) or Phusion (New England
Biolabs) polymerases with the following oligonucleotide pairs
before cloning into pcDNA3.1/V5HisTOPO (Invitrogen): pEQ1336
(gp145[187-632], #899 50-ACCATGGCCAGGGAAAGCTACG-30 and
#900 50-GGAACACTCCTCGTCGCTGG-30); pEQ1337 (gp145[356-
632], #901 50-ACCATGGCCTATCTGCCCGCCAGC-30and #900);
pEQ1412 (gp145[1-186], #902 50-ACCATGCACCGAGGCGTTTC-30
and #988 50 CATCTTGACCATCTTCAGCTGCA 30); pEQ1353
(gp145[1-355], #902 and #903 50-GTCCAGGTACTCGGCGCT-30);
pEQ1347 (gp145[1-512], #902 and #904 50-GAGA-
TACGTGTTTCCCGGCAG-30); pEQ1352 (gp145[1-566], #902 and
#905 50-GTCGTAGCGCTCGTCGGTG-30); pEQ1355 (gp145[187-
355], #899 and #903).
pCS2þBirA expressing the Escherichia coli biotin ligase was
obtained from Bruce Clurman (FHCRC). Biotinylation signal (Bio)
tagged TRS1[1-738], pEQ1133, was engineered by digesting the
Bio-His tagged pEQ1068 (Child and Geballe, 2009) with PmeI and
BstBI, blunting with the Klenow fragment, and re-ligating. This
plasmid was then digested with Asp718 and NotI and TRS1 was
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enzymes to make pEQ1376, Bio-tagged gp145.
GPCMV infection
Conﬂuent GPL cells were infected with GPCMV at a multi-
plicity of infection (MOI) of 3. Virus was allowed to adsorb to the
cells for 2 h at 37 1C before the inoculum was aspirated and
replaced with fresh media. At 4 days post infection, cells were
either harvested directly for dsRNA-binding assays or radiola-
beled with EasyTag Express35S Protein Labeling Mix (50 mCi/ml;
Perkin-Elmer) for 2 h, washed once with PBS, harvested by
scraping, and lysed with Buffer A (100 mM KCl, 20 mM HEPES
[pH 7.5], 10% glycerol, 5 mM MgOAc, 1 mM dithiothreitol, 1 mM
benzamidine (Sigma), and 1% NP40) (Hakki and Geballe, 2005).
dsRNA-binding assay
dsRNA poly I:C agarose beads were prepared as described
previously (Langland et al., 1995). Binding assays using GPCMV-
infected cells were performed by harvesting the cells and lysing in
Buffer A by incubating for 20 min on ice and pelleting the nuclei
by centrifuging (16,000g) for 15 min at 4 1C. The lysate was split
between samples containing a mixture of 10 or 20% dsRNA
agarose beads in carrier Sepharose CL6B (SigmaAldrich) or with
control Sepharose CL6B alone and incubated for 2 h at 4 1C on a
rotating mixer. After binding, the beads were pelleted (845g,
3 min) and washed in Buffer A 3 or 4 times after which bound
proteins were denatured, separated on 10% SDS-PAGE gels and
visualized either by silver-staining or autoradiography. To test the
dsRNA-binding of an individual protein, the indicated plasmid
was in vitro translated using the TNT Quick Coupled Transcrip-
tion/Translation System (Promega) and radiolabeled with [35S]
(Easy Tag Express35S Protein Labeling Mix, Perkin-Elmer) per
reaction. The in vitro translated protein was then diluted with
Buffer A and subjected to the above binding assay. For competi-
tion assays, samples were incubated with either 200 mg of free
poly I:C (Sigma) or salmon sperm DNA (Sigma) competitor for 1 h
at 4 1C on a rotating mixer before addition of the dsRNA bead
mixture. Following separation on 10% SDS-PAGE gels and ﬂuoro-
graphic enhancement (EN3HANCE [PerkinElmer]), samples were
visualized by autoradiography.
LC–MS/MS analysis
Samples from a GPCMV infection that had been subjected to a
dsRNA-binding assay were run on a 10% SDS-PAGE gel before
being stained and destained using the SilverQuest kit (Invitrogen).
The bands were excised, dehydrated using acetonitrile, and
digested overnight with 5 ng/mL trypsin (Promega) in 50 mM
ammonium bicarbonate at 37 1C. The peptides were ﬁrst
extracted using 5% v/v formic acid in water after 30 min incuba-
tion, then with acetonitrile. The pooled extracts were dried in a
speed vac and cleaned using ZipTipTM C18 (Millipore) before mass
spectrometry (MS).
Liquid chromatography (LC)–tandemmass spectrometry (MS/MS)
analysis was performed using a LTQ Orbitrap mass spectrometer
(Thermo Fisher Scientiﬁc). The LC system was conﬁgured in a
vented format that consisted of a fused-silica nanospray needle
packed in-house with Magic C18 AQ 100A reverse-phase media
(Michrom Bioresources Inc.) and a trap containing Magic C18 AQ
200A reverse-phase media (Licklider et al., 2002). The peptide
samples were loaded onto the column and chromatographic
separation was performed using a two-mobile-phase solvent
system consisting of 0.1% formic acid in water (A) and 0.1% acetic
acid in acetonitrile (B). The mass spectrometer operated in adata-dependent MS/MS mode over the m/z range of 400–1800.
For each cycle, the ﬁve most abundant ions from each MS scan
were selected for MS/MS analysis using 35% normalized collision
energy. Selected ions were dynamically excluded for 45 s.
Raw MS/MS data were submitted to the Computational Pro-
teomics Analysis System (CPAS), a web-based system built on the
LabKey Server and searched using the X! Tandem search engine
against a protein database derived from the GPCMV genome
sequence (GenBank ID: NC_011587.1) and the guinea pig protein
database (Broad Institute: cavPor3), which also included addi-
tional common contaminants such as human keratin (Craig and
Beavis, 2004; Rauch et al., 2006). The search output ﬁles were
analyzed and validated by ProteinProphet (Nesvizhskii et al.,
2003). Proteins and peptides with a probability score of 1.0 were
accepted.
VVDE3L rescue by transient transfection
Triplicate wells of subconﬂuent HeLa, GPC-16, or COS-7 cells
were transfected with the indicated plasmid using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions.
24 h post transfection, cells were infected with VVDE3L at a MOI
of 1 and viral replication was quantiﬁed by 4-methylumbelliferyl
b-D-galactopyranoside (MUG) assay at 24 h post infection as
described previously (Hakki and Geballe, 2005).
HeLa PKRKD reporter gene rescue assay
Subconﬂuent HeLa PKRKD cells in 24 well plates were trans-
fected with 2 ml Lipofectamine 2000 (Invitrogen) per well and the
following amounts of plasmid DNA: 0.05 mg of SEAP reporter
(pEQ886), 0.1 mg of knockdown resistant PKR or EGFP (SR#329 or
pEQ1338), and 0.65 mg of EGFP or PKR antagonist (pEQ1159,
pMTE3L, pEQ1180, or pKTS786) (Rothenburg et al., 2009). The
transfection medium was replaced with fresh medium after 24 h.
At 48 h post transfection, the medium was harvested and SEAP
activity was measured as described previously (Janzen and
Geballe, 2004).
Northern blot
RNA was harvested from transfected HeLa PKRKD cells using
Trizol reagent (Invitrogen) and resolved on a 1% formaldehyde
agarose gel prior to capillary transfer to a supported nitrocellulose
membrane (Optitran, GE Healthcare). Northern hybridization was
performed as described previously (Child et al., 2004) using a
probe speciﬁc to SEAP, which was generated from a fragment of
pEQ886 gel isolated following digestion with XhoI and HindIII.
The blot was visualized by phosphorimager analysis (Typhoon
Trio [GE Healthcare]) and bands quantiﬁed using the ImageQuant
software.
Avidin agarose pull-down
Subconﬂuent COS-7 cells in 6 well plates were transfected
using Lipofectamine 2000 with a mixture of 1.3 mg of each of
3 plasmids: (1) pCS2þBirA, (2) Bio-tagged TRS1 (pEQ1133) or
gp145 (pEQ1376), and (3) a plasmid expressing 6X-His-tagged
protein. 24 h post transfection, the transfection medium was
replaced with medium supplemented with 35 mM Biotin (Sigma).
At 48 h post transfection, cells were harvested by trypsanization
and lysed in 110 ml of radioimmunoprecipitation assay buffer
([RIPA] 50 mM Tris–HCl, 150 mM NaCl, 0.1% sodium deoxycho-
late, 0.05% SDS, and 1% Triton X-100) by incubation for 20 min on
ice followed by centrifugation (16,000g) for 15 min at 4 1C to
pellet the nuclei. After reserving a portion, the lysate was added
C.J. Bierle et al. / Virology 433 (2012) 157–166 165to avidin agarose (Pierce) and incubated on a rotating mixer at
4 1C for 2 h. After binding, the beads were pelleted (845g, 3 min)
and washed 3X with RIPA buffer before denaturing and separation
by 10% SDS-PAGE and visualization by immunoblot as
described below.
Immunoblot analyses
Unless otherwise noted, cells were lysed with 2% SDS, DNA
sheared with a Bransonic bath sonicator, and protein concentra-
tions were determined using ﬂuoraldehyde o-phthalaldehyde
(Pierce) assay (Geballe and Mocarski, 1988). Equivalent amounts
of protein were separated by SDS-PAGE prior to transfer to
polyvinylidene diﬂuoride membranes (GE Life Sciences) by elec-
troblotting. Proteins were detected using the WesternStarTM
chemiluminescent detection system (Applied Biosystems) accord-
ing to the manufacturer’s instructions using the following com-
mercial primary antibodies diluted 1:1000: Actin (Sigma A-2066),
PentaHis (Qiagen, 34660), and PKR (Santa Cruz Biotechnology,
Inc. sc6282). Biotinylated proteins were detected using avidin-
alkaline phosphatase conjugate (Avidx-AP, Applied Biosystems).Acknowledgments
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